Ghana Hosts Regional Push to Turn Continental Procurement Pledge Into Market Reality for African Drugmakers

The National Vaccine Institute (NVI) and the Africa Centres for Disease Control and Prevention (Africa CDC) convene a two-day regional meeting in Accra starting Tuesday, bringing manufacturers, regulators and procurement officials together to move the African Pooled Procurement Mechanism (APPM) from a signed agreement into an operating continental market.

Some 70 participants, about 40 of them government and regional delegates, are expected at the November 10–11 meeting, which will focus on the practical mechanics of the mechanism: country enrolment, the APPM Supply Catalogue, technical specifications, demand aggregation and forecasting, quality assurance and regulatory requirements, tendering status, and financing and implementation timelines.

The stakes are substantial for Ghana. Having signed a Memorandum of Understanding with Africa CDC on August 21, 2026, Ghana is now among eight African Union member states formally participating in the APPM, with another 15 having expressed interest . For qualified Ghanaian manufacturers, the mechanism offers a route beyond a domestic market of roughly 33 million people into a continental market of approximately 1.4 billion.

Early Results, Larger Ambitions

The APPM was established by Africa CDC pursuant to African Union decisions as a demand-aggregation tool to strengthen purchasing power, improve access to affordable quality-assured products, and create predictable markets for African manufacturers. Its first tender, announced in May 2026, covered ten priority reproductive, maternal, newborn and child health medicines across ten member states and secured average savings of 45 percent below member state benchmarks, with African manufacturers featuring in five of the ten products.

To date, 89 manufacturers from 15 African countries have registered with the APPM, according to Africa CDC . The next phase involves establishing framework agreements covering product specifications, procurement volumes and competitive pricing—the substance of what this week’s Accra meeting is designed to advance.

The mechanism is central to the African Union’s target of meeting 60 percent of the continent’s health product needs from local production by 2040. Africa CDC officials have framed the APPM explicitly as a market-shaping instrument, not merely a purchasing arrangement.

“We have to create the conditions that give manufacturers confidence to invest, scale production and supply the continent,” Dr Mariatou Tala Jallow, Director of the APPM at Africa CDC, said at a consultative workshop in Addis Ababa in October. “If we want African manufacturers to invest in Africa, we must give them a market in return for those investments” .

Ghana’s Positioning

Ghana’s participation is intended to complement domestic efforts to create predictable demand through an Advance Purchase Commitment mechanism. The country’s Food and Drugs Authority retains exclusive regulatory authority over marketing authorisation, import control, batch release and post-market surveillance for products supplied through the mechanism.

Ahead of the meeting, NVI Chief Executive Officer Dr. Sodzi Sodzi-Tettey framed the gathering as a chance to widen the opportunity beyond the initial participants. “Just a year ago, access to a continental market seemed like a distant dream,” he said. “Today, not only is Ghana a member of the APPM, a few products are reaching millions in Africa. With this meeting, we expand the opportunity to all pharmaceutical and vaccine manufacturers in Ghana and West Africa. It is an opportunity to scale for impact.”

The meeting is supported by PharmaVax Ghana, a programme co-financed by the European Union and German Development Cooperation and implemented by GIZ.

What Participants Will Agree

According to the NVI, the workshop aims to build a common understanding of the APPM operational model and clarify roles for Africa CDC, member states, procuring entities and manufacturers. Participants will seek agreement on demand aggregation and product prioritisation, including requirements for the Supply Catalogue and forecasting; clarify supplier participation, quality assurance and regulatory requirements; and identify actions to strengthen African manufacturers’ readiness for pooled procurement.

They are also expected to agree on procurement, financing and implementation arrangements, including a time-bound roadmap for operationalising the APPM in Ghana and supporting regional market access for priority health products.

---

Background: From Decision to Market

The APPM was established by an African Union Assembly decision in February 2024, but its operational phase has accelerated only in 2026, with the first tender results and the expansion of membership. The mechanism is designed to complement, not replace, national and regional procurement systems—a concession to member states wary of ceding sovereignty over purchasing. Its credibility now rests on whether framework agreements can deliver the volumes and predictability that would justify manufacturers’ investments in capacity. For Ghana, the meeting represents a test of whether its early membership translates into contracts for local firms rather than remaining a diplomatic cause.